Insider Trading Alert - BMR, SEE And ASPS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Aug. 13, 2014, 91 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,704.50 to $121,177,500.00.

Highlighted Stocks Traded by Insiders:

BioMed Realty (BMR) - FREE Research Report

McDevitt Matthew G, who is Executive VP, Real Estate at BioMed Realty, sold 16,000 shares at $22.01 on Aug. 13, 2014. Following this transaction, the Executive VP, Real Estate owned 122,328 shares meaning that the stake was reduced by 11.57% with the 16,000-share transaction.

The shares most recently traded at $22.17, up $0.16, or 0.72% since the insider transaction. Historical insider transactions for BioMed Realty go as follows:

  • 4-Week # shares sold: 7,000
  • 12-Week # shares sold: 7,000
  • 24-Week # shares sold: 44,771

The average volume for BioMed Realty has been 1.4 million shares per day over the past 30 days. BioMed Realty has a market cap of $4.3 billion and is part of the financial sector and real estate industry. Shares are up 22.57% year-to-date as of the close of trading on Wednesday.

BioMed Realty Trust, Inc. operates as a real estate investment trust (REIT) that focuses on providing real estate to the life science industry in the United States. The stock currently has a dividend yield of 4.58%. The company has a P/E ratio of 83.9. Currently, there are 7 analysts who rate BioMed Realty a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BMR - FREE

TheStreet Quant Ratings rates BioMed Realty as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, impressive record of earnings per share growth, increase in net income, revenue growth and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full BioMed Realty Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

BioMed Realty (BMR) Marked As A Barbarian At The Gate

3 Hold-Rated Dividend Stocks: SEAS, BMR, TGH

3 Real Estate Stocks Moving The Industry Upward

BioMed Realty Just One of Blackstone's Latest Multi-Billion-Dollar Deals

Jim Cramer -- REIT Sector Hammered but Still Buying Opportunities